In a recent article from Biomed Central, the importance of epigenomics and the Human Genome Project and more recent cancer- focused initiatives are discussed.
A new paradigm being explored is the idea of C2c (cancer to chronic disease) approach, which proposes that a new goal in oncology should be to turn cancer into a clinically manageable chronic disease.
The article provides detailed information about epigenomics, exploring the process of identifying complex patterns of mutations associated with the initiation and progression of disease, as well as exploring drugs that target specific regulators of epigenetic alterations.
Dr. Tamas Ordog, one of the members of the Life Raft Group’s research team, has been in the forefront of this type of research at the Mayo Clinic.
Click here to read the full article about epigenomics.